Chapter 5. Peptide Manufacturing Methods and Challenges

S. Kota
{"title":"Chapter 5. Peptide Manufacturing Methods and Challenges","authors":"S. Kota","doi":"10.1039/9781788016445-00111","DOIUrl":null,"url":null,"abstract":"Peptides are manufactured commercially by liquid- or solid-phase peptide synthesis, by hybrid synthesis using both solid- and solution-phase synthesis or by using recombinant DNA technologies. The technology applied to commercial manufacturing is determined by the size and nature of the peptide. Since the impurities in peptides tend to be generally similar to those in the product of interest, downstream processing steps such as purification and isolation are significant for producing highly purified active peptide pharmaceutical ingredients that meet the stringent regulatory requirements.","PeriodicalId":20009,"journal":{"name":"Peptide Therapeutics","volume":"21 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Peptide Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1039/9781788016445-00111","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Peptides are manufactured commercially by liquid- or solid-phase peptide synthesis, by hybrid synthesis using both solid- and solution-phase synthesis or by using recombinant DNA technologies. The technology applied to commercial manufacturing is determined by the size and nature of the peptide. Since the impurities in peptides tend to be generally similar to those in the product of interest, downstream processing steps such as purification and isolation are significant for producing highly purified active peptide pharmaceutical ingredients that meet the stringent regulatory requirements.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
第五章。肽制造方法和挑战
多肽通过液相或固相多肽合成、固相和固相混合合成或重组DNA技术进行商业化生产。应用于商业生产的技术是由肽的大小和性质决定的。由于多肽中的杂质通常与目标产品中的杂质相似,因此纯化和分离等下游处理步骤对于生产高度纯化的活性多肽药物成分具有重要意义,这些活性多肽药物成分符合严格的监管要求。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Peptide Therapeutics: Fundamentals of Design, Development, and Delivery Chapter 5. Peptide Manufacturing Methods and Challenges Chapter 2. Regulatory Perspective on Synthetic Peptides in Europe Chapter 13. Assessing the Impact of Functional Excipients on Peptide Drug Product Attributes During Pharmaceutical Development Chapter 9. Impurity Characterization and Quantification by Liquid Chromatography–High-resolution Mass Spectrometry
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1